The use of small-molecule inhibitors (Erlotinib, Gefintib, Labatinib, etc.)and monoclonal antibodies targeted against EGFR (Cetuximab and Panitututmab) is a common therapeutic strategy in several solid tumors, including gliomas. Here, EGFR is linked to central nervous system cancer.